NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 D-cycloserine and Lurasidone, an oral, fixed dosed combination of D-cycloserine/lurasidone that earned food and drug administration-designated as breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 ketamine, which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior ASIB. The company has a partnership with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Current Quarter	$-0.05	Next Quarter	$-0.03
Current Year	$-0.12	Next Year	$0.87
QoQ Growth	+40.0%	YoY Growth	+825.0%
3Y EPS CAGR	+51.8%	Target Price	$38.25
Consensus	Buy	Upside	+787.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NRXP	$4.31	+33.85%	4.32M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NRXP	$4.31	+33.9%	4.32M
3
4
5
6

NRXP

NRXP

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get NRX Pharmaceuticals Inc. Data in Excel

Get NRX Pharmaceuticals Inc. Data in Excel